Sea Change In China’s Anti-Cancer Market Shares
This article was originally published in PharmAsia News
China's hospitals are increasingly turning to alkaloid products such as paclitaxel and docetaxel to treat cancer while immunostimulant anti-cancer products see a decline in use, despite owning the largest market share
You may also be interested in...
BEIJING - In the latest twist in one of the most closely followed pharmaceutical patent disputes ever in China, an executive at Sanofi-Aventis said the company will appeal the recent invalidation of its patent for an injectable anti-cancer drug in Beijing
SHANGHAI - Sanofi-Aventis will expand its footprint in China by collaborating with Tianjin's Institute of Hematology and Blood Diseases Hospital (IHBDH) in the field of cancer stem cells, the French drug maker announced Sept. 14
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).